Mereo BioPharma Group plc
NASDAQ: MREO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Denise Vera Scots-Knight
- Employees
- 36
- Headquarters
- London, United Kingdom
- IPO year
- 2019
- Market cap
- $48.6M
- Website
- https://www.mereobiopharma.com
Loading MREO…
Loading profile data…Frequently asked questions about MREO
What does Mereo BioPharma Group plc (MREO) do?
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an...
Where does MREO trade?
Mereo BioPharma Group plc (MREO) trades on the NASDAQ Global Market.
What sector is MREO in?
Mereo BioPharma Group plc (MREO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Mereo BioPharma Group plc?
Denise Vera Scots-Knight is the chief executive officer of Mereo BioPharma Group plc (MREO).
Where is Mereo BioPharma Group plc headquartered?
Mereo BioPharma Group plc is headquartered in United Kingdom.
Does MREO pay a dividend?
Mereo BioPharma Group plc (MREO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MREO go public?
Mereo BioPharma Group plc (MREO) completed its initial public offering in 2019.
Is MREO an ADR?
Yes — MREO is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Mereo BioPharma Group plc reporting and dividends follow the underlying issuer.